Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,598 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.
Tasaki Y, Ito N, Mimura Y, Sugiyama Y, Ogawa R, Shimura T, Nakamura M, Kawakita D, Hamamoto S, Uemura T, Yokota K, Iida M, Odagiri K, Kimura Y, Hotta Y, Komatsu H, Okuda K, Niimi A, Yasui T, Iwasaki S, Morita A, Kataoka H, Takiguchi S, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: morita a. Asia Pac J Clin Oncol. 2024 Apr 29. doi: 10.1111/ajco.14073. Online ahead of print. Asia Pac J Clin Oncol. 2024. PMID: 38682421
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Blauvelt A, Rich P, Sofen H, Strober B, Merola JF, Lebwohl M, Morita A, Szepietowski JC, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee S, Thaçi D. Blauvelt A, et al. Among authors: morita a. J Am Acad Dermatol. 2024 Apr;90(4):775-782. doi: 10.1016/j.jaad.2023.11.060. Epub 2023 Dec 18. J Am Acad Dermatol. 2024. PMID: 38122848 Free article. Clinical Trial.
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H; ERASURE Study Japanese subgroup. Ohtsuki M, et al. Among authors: morita a. J Dermatol. 2014 Dec;41(12):1039-46. doi: 10.1111/1346-8138.12668. Epub 2014 Oct 30. J Dermatol. 2014. PMID: 25354738 Clinical Trial.
Exploring patient background and biomarkers associated with the development of dupilumab-associated conjunctivitis and blepharitis.
Kido-Nakahara M, Onozuka D, Izuhara K, Saeki H, Nunomura S, Takenaka M, Matsumoto M, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Saito R, Okano T, Miyagaki T, Aoki N, Nakajima K, Ichiyama S, Tonomura K, Nakagawa Y, Tamagawa-Mineoka R, Masuda K, Takeichi T, Akiyama M, Ishiuji Y, Katsuta M, Kinoshita Y, Tateishi C, Yamamoto A, Morita A, Matsuda-Hirose H, Hatano Y, Kawasaki H, Fukushima-Nomura A, Ohtsuki M, Kamiya K, Kabata Y, Abe R, Mitsui H, Kawamura T, Tsuji G, Furue M, Katoh N, Nakahara T. Kido-Nakahara M, et al. Among authors: morita e, morita a. Allergol Int. 2024 Apr;73(2):332-334. doi: 10.1016/j.alit.2023.12.001. Epub 2023 Dec 27. Allergol Int. 2024. PMID: 38151410 Free article. No abstract available.
International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council.
Choon SE, van de Kerkhof P, Gudjonsson JE, de la Cruz C, Barker J, Morita A, Romiti R, Affandi AM, Asawanonda P, Burden AD, Gonzalez C, Marrakchi S, Mowla MR, Okubo Y, Oon HH, Terui T, Tsai TF, Callis-Duffin K, Fujita H, Jo SJ, Merola J, Mrowietz U, Puig L, Thaçi D, Velásquez M, Augustine M, El Sayed M, Navarini AA, Pink A, Prinz J, Turki H, Magalhães R, Capon F, Bachelez H; IPC Pustular Psoriasis Working Group. Choon SE, et al. Among authors: morita a. JAMA Dermatol. 2024 May 1. doi: 10.1001/jamadermatol.2024.0915. Online ahead of print. JAMA Dermatol. 2024. PMID: 38691347
1,598 results